# Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD

> **NCT00577837** · PHASE2 · COMPLETED · sponsor: **Warner Chilcott** · enrollment: 370 (actual)

## Conditions studied

- Postmenopausal

## Interventions

- **DRUG:** risedronate
- **DRUG:** risedronate
- **DRUG:** risedronate
- **DRUG:** experimental

## Key facts

- **NCT ID:** NCT00577837
- **Lead sponsor:** Warner Chilcott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 370 (ACTUAL)
- **Last updated:** 2013-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00577837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00577837, "Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00577837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*